Title: Tigecycline
CAS Registry Number: 220620-09-7
CAS Name: (4S,4aS,5aR,12aS)-4,7-Bis(dimethylamino)-9-[[[(1,1-dimethylethyl)amino]acetyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide
Additional Names: 9-t-butylglycylamido-minocycline; TBG-MINO
Manufacturers' Codes: GAR-936
Trademarks: Tygacil (Wyeth)
Molecular Formula: C29H39N5O8
Molecular Weight: 585.65
Percent Composition: C 59.47%, H 6.71%, N 11.96%, O 21.86%
Literature References: Broad spectrum glycylcycline antibiotic; semisynthetic tetracycline analogue. Prepn: J. J. Hlavka et al., EP 536515; eidem, US 5494903 (1993, 1996 both to Am. Cyanamid); P.-E. Sum, P. Petersen, Bioorg. Med. Chem. Lett. 9, 1459 (1999). In vivo pharmacodynamics: M. L. van Ogtrop et al., Antimicrob. Agents Chemother. 44, 943 (2000). In vitro activity vs clinical bacterial isolates: A. C. Gales, R. N. Jones, Diagn. Microbiol. Infect. Dis. 36, 19 (2000); D. Milatovic et al., Antimicrob. Agents Chemother. 47, 400 (2003). Mode of action study: G. Bauer et al., J. Antimicrob. Chemother. 53, 592 (2004). Clinical pharmacology: A. K. Meagher et al., Diagn. Microbiol. Infect. Dis. 52, 165 (2005). Clinical evaluation in complicated skin and skin-structure infections: R. G. Postier et al., Clin. Ther. 26, 704 (2004); E. J. Ellis-Grosse et al., Clin. Infect. Dis. 41, S341 (2005); in complicated intra-abdominal infections: T. Babinchak et al., ibid. S354. Review of chemistry, pharmacology and clinical development: E. Rubinstein, D. Vaughan, Drugs 65, 1317-1336 (2005); R. A. Squires, R. G. Postier, Expert Opin. Invest. Drugs 15, 155-162 (2006).
Properties: Orange powder or cake.
Therap-Cat: Antibacterial.
Keywords: Antibacterial (Antibiotics); Tetracyclines. |